Teva Pharma (TEVA) PT Lowered to $64 at Mizuho; 'Buy' Maintained

August 25, 2016 12:27 PM EDT
Get Alerts TEVA Hot Sheet
Price: $32.59 -0.37%

Rating Summary:
    18 Buy, 21 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 18 | Down: 19 | New: 11
Trade TEVA Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Mizuho Securities analyst Irina Koffler lowered her price target on Teva Pharma (NYSE: TEVA) price to $64.00 (from $70.00) following a negative IPR decision on two Copaxone patents but maintained a Buy rating. The analyst has gotten more conservative in their outer year expectations.

Koffler commented, "Our Buy thesis is predicated on valuation rather than any particular catalyst, though additional visibility into the recently acquired generics business and pipeline could serve to drive share momentum in 2H:16."

For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.

Shares of Teva Pharma closed at $51.63 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

Irina Koffler

Add Your Comment